Physician profile
Dax M Eckard
NPI 1932102779
$4,850.34
in general payments reported to CMS, 2019-2025
28 companies · $840 in 2025
The $840 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $271 · 2021: $498 · 2022: $945 · 2023: $842 · 2024: $795 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,451 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,451.24 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,018.25 | 2021-2025 | Acthar |
| Abbvie INC. | $453.71 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Alcon Vision LLC | $401.47 | 2019-2025 | Clareon, Total30, Precision7 |
| Johnson & Johnson Vision Care, INC. | $360.12 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $251.40 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Rxsight INC | $247.99 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Oyster Point Pharma, INC. | $239.44 | 2022-2025 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $239.28 | 2019-2022 | |
| Optos, INC. | $228.88 | 2019 | |
| Harrow Eye, LLC | $179.19 | 2023-2025 | Iheezo, Triesence |
| Novartis Pharmaceuticals Corporation | $169.69 | 2019-2023 | |
| Glaukos Corporation | $150.72 | 2025 | Photrexa Viscous and Photrexa, Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $143.82 | 2019-2021 | |
| Ocular Therapeutix, INC. | $101.40 | 2023-2025 | Dextenza |
| Eyevance Pharmaceuticals LLC | $85.67 | 2021-2023 | Tobradex St |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $85.37 | 2021-2023 | Oxervate |
| Sun Pharmaceutical Industries INC. | $79.67 | 2019-2023 | Cequa |
| Aerie Pharmaceuticals, INC. | $77.56 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $64.78 | 2024-2025 | Purified Cortrophin Gel, Iluvien |
| Biotissue Holdings INC. | $52.53 | 2020-2024 | |
| Tarsus Pharmaceuticals, INC. | $44.72 | 2024-2025 | Xdemvy |
| Coopervision INC. | $40.46 | 2022 | |
| Rayner Intraocular Lenses Limited | $29.10 | 2024 | Omidria |
| Sight Sciences, INC. | $28.19 | 2023-2025 | Tearcare System |
| Johnson & Johnson Surgical Vision, INC. | $28.04 | 2019 | |
| Shire North American Group INC | $19.57 | 2019 | |
| Iridex Corporation | $15.63 | 2019 | |
| New World Medical,INC. | $13.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dax Eckard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.